MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/17562848251374638

Медицинская библиотека · Therapeutic advances in gastroenterology · 2025

Tofacitinib in acute severe ulcerative colitis: review addressing seven key unmet needs.

Nguyen Chuong Dinh, Dang Luan Minh, Vo Thong Duy, Bui Hoang Huu, Kim Eun Soo, Mak Joyce Wing Yan, Ooi Choon Jin

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Tofacitinib, an oral Janus kinase (JAK) inhibitor, shows promise as a rescue therapy for acute severe ulcerative colitis (ASUC), a life-threatening condition marked by high colectomy rates. This narrative review synthesizes evidence from randomized controlled trials (RCTs), observational studies, and systematic reviews. The efficacy of tofacitinib has been documented, with an 83.01% day-7 response rate in the TACOS trial and 79.9%-86% 90-day colectomy-free survival in steroid-refractory ASUC. However, seven unmet needs impede the adoption of tofacitinib treatment for managing ASUC: (1) a lack of head-to-head RCTs comparing tofacitinib not only to standard rescue therapies like infliximab and ciclosporin but also to other JAK inhibitors like upadacitinib, (2) uncertainty in optimal dosing and duration, (3) ambiguity in positioning tofacitinib in the treatment algorithm, (4) undefined patient selection criteria, notably for those with prior biologic exposure, (5) limited long-term efficacy and cost-utilization data, (6) unresolved safety risks (e.g., infections, thrombosis), and (7) underexplored potential for combination therapy. These gaps undermine the widespread use of tofacitinib in reducing surgical burden and improving outcomes. Collaborative research-especially multi-center RCTs comparing tofacitinib to infliximab, ciclosporin, and next-generation JAK inhibitors-is vital for establishing evidence-based protocols. Addressing these needs could optimize tofacitinib-based ASUC management, offering a rapid, oral alternative to enhance patient care.

Для цитирования: Nguyen Chuong Dinh, Dang Luan Minh, Vo Thong Duy, Bui Hoang Huu, Kim Eun Soo, Mak Joyce Wing Yan, Ooi Choon Jin. Tofacitinib in acute severe ulcerative colitis: review addressing seven key unmet needs.. Therapeutic advances in gastroenterology. 2025. DOI: 10.1177/17562848251374638.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.